The current study was conducted with the objective to validate the Mantle-cell lymphoma International Prognostic Index (MIPI) for patients with Mantle-cell lymphoma (MCL). Relevant data was collected from 958 patients with MCLwith median age of 65 years to evaluate the prognostic value of MIPI. The primary outcomes measured were overall survival (OS) and time to treatment failure (TTF). Independent prognostic factors included MIPI, age, performance status, lactate dehydrogenase level, and WBC count  Patients were categorized into low (83%),intermediate (63%) and high-risk (34%), groups based on their MIPI score. Hazard ratios for OS within groups were calculated. This study concluded that MIPI tool can be an effective prognostic predictor clinically for diagnosing clinical outcome in MCL.

The aim of this study was to validate the MIPI score in Mantle cell lymphoma (MCL) patients treated with strong immunochemotherapy. 158 patients with MCL were involved in the study treated with first line immnunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. Overall survival was studied in the patients after applying MIPI scores to them. Results showed survival was predicted significantly better MIPI (P < .001) when compared with the International Prognostic Index (P > .004). The study concluded that MIPI simple and feasible tool than others for predicting the survival in patients with MCL

The aim of this study was to validate the MIPI scores in patients with Mantle cell lymphoma (MCL) for prediction of overall survival (OS). Diagnosis of MCL was confirmed in patients by utilizing various immnunohistochemistry techniques. Outcomes measured were ECOG performance status, age, leukocyte count, and lactic dehydrogenase. Patients were divided into low, intermediate and high-risk group according to their MIPI scores. 51 and 29 months was the OS in intermediate and high risk groups respectively. This study concluded that MIPI score can be effectively used clinically to predict OS in patients with MCL

This study aimed to further validate the R-MIPI (Revised MIPI) score in patients treated with rituximab-containing chemotherapy. 501 patients with Mantle cell lymphoma were involved in the study and were evaluated for prognostic factors adjusted by the rituximab treatment. Patients were divided into low, intermediate high, internmediate low and high risk groups. New risk factors included in R-MIPI were assessment of albumin and bone marrow involvement. Five year overall survival was the primary outcome observed. 5 year overall survival in low, low-intermediate, high-intermediate and high R-MIPI groups was 92%, 75%, 61% and 19%, respectively. This study conclude that R-MIPI was more advanced and clinically acceptable criteria than the MIPI score

This study was conducted with aim to check the performance of MIPI score in patients with mantle cell lymphoma (MCL). 455 patients with advanced MCL were recruited in the study and MIPI scores were calculated. Multiple Cox regression was utilized to develop MIPI score. Results showed that MIPI score was more accurate in calculating the overall survival (OS) in patients with MCL than other scores. This study concluded that MIPI is a great tool to determine risk-adapted treatment approaches in patients with advanced stage MCL.